

NEWS RELEASE

Publication on Provid MS drug PV-267 Featured by Journal of Immunology.

Monmouth Junction, NJ, November 15, 2013 – The first publication on Provid’s MS drug, PV-267, appears in the November 15, 2013 issue of *The Journal of Immunology*. The article is featured in the “In This Issue” section that highlights articles considered to be among the top 10% of articles published in the journal. In addition, a corresponding *ImmunoCast* of the “In This Issue” section is produced for each issue, and can be found on *The Journal of Immunology* web site at: <http://www.jimmunol.org/rss/jipodcast.xhtml>.

The publication is co-authored by Niannian Ji, Animesh Somanaboeina, Aakanksha Dixit, Kazuyuki Kawamura, Neil J. Hayward, Christopher Self, Gary L. Olson and Thomas G. Forsthuber.

The research described was funded through Provid’s partnership with Fast Forward, LLC, the venture arm of the National Multiple Sclerosis Society, and by a grant from the National Institute of Neurological Diseases and Stroke.

About Provid

Provid Pharmaceuticals Inc. is a drug discovery company that has expertise in structure-aided design, medicinal chemistry, and peptide mimetics technology. The company has applied this capability to programs in autoimmune disease, leading to PV-267 for MS.

Contact:

Dr. Gary L. Olson

Provid Pharmaceuticals Inc.

Tel: (732) 565-1101 x 626

Email: gary.olson@provid.com

www.provid.com